Abata Therapeutics is a clinical-stage biotech company focused on transforming lives of patients with autoimmune disease using regulatory T cell (Treg) therapies engineered with T cell receptors (TCRs). Tregs are immunosuppressive and have the ability to dampen unwanted and rampant inflammatory responses, stop immune-mediated destruction, restore homeostasis, and promote repair in damaged tissues. Abata is currently evaluating its Treg cell therapy for progressive multiple sclerosis in a Phase 1 clinical trial, which was initiated in 2024.
Abata Therapeutics has licensed the LentiBOOST™ technology to increase transduction efficiency of the engineered Treg therapies. LentiBOOST technology facilitates viral entry into target cells, increasing the likelihood of successful gene delivery and expression by enhancing transduction efficiency and VCN. The adoption of LentiBOOST technology in T cell research and advanced T cell therapy development has been growing rapidly, with studies demonstrating its efficacy in CAR-T and CAR-Treg production as well as TCR gene delivery in T cells.
We are excited to support the work of Abata Therapeutics in exploring these new avenues of Treg therapies that can impact millions affected worldwide by autoimmune disease. Learn more by visiting Abata Therapeutics webpage and exploring our LentiBOOST resources below.
LentiBOOST GMP Grade: Not for Diagnostic Use. Other applications must be authorized by a license from Revvity.
